Posts by Bob S. Carter, MD, PhD
-
Co-transplantation of Regulatory T Cells Improves Cell Replacement Therapy for Parkinson's Disease
Research at Massachusetts General Hospital suggests a novel strategy for enhancing the efficacy and safety of cell replacement therapy in the nervous system: co-transplantation of dopamine progenitor cells with regulatory T cells to modulate the host immune response triggered by needle trauma.
-
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma
Massachusetts General Hospital researchers have developed TanCART, the first chimeric antigen receptor T cell that targets EGFRvIII and IL-13R?2 simultaneously, and found it was effective in vitro and in murine models of heterogeneous glioblastoma, including patient-derived xenografts.
-
The Future of Neurosurgery and Neuroscience at Mass General: Q&A With Bob S. Carter, MD, PhD
Bob S. Carter, MD, PhD, is the chief of the Department of Neurosurgery at Massachusetts General Hospital. In this Q&A, Dr. Carter elaborates on intraoperative molecular diagnostics. Dr. Carter is also a 2021 Congress of Neurological Surgeons (CNS) honored guest.
-
Review: Challenges in Discovering Extracellular Vesicle–based Cancer Biomarkers
Anudeep Yekula, MD, Leonora Balaj, PhD, and Bob S. Carter, MD, PhD, of the Department of Neurosurgery, highlight hurdles in the process of developing extracellular vesicle–based cancer biomarkers, from discovery to clinical application.
-
Genotyping Assay Accelerates Diagnosis of Primary CNS Lymphoma, Detects Other Hematologic Malignancies
Bob S. Carter, MD, PhD, and Ganesh M. Shankar, MD, PhD, of the Department of Neurosurgery, have developed a targeted genotyping assay that shortens the time to diagnosis of primary central nervous system lymphoma and may reduce the need for neurosurgical biopsy.
-
New Advances in Glioma Surgery
Bob S. Carter, MD, PhD, chief of the Department of Neurosurgery at Massachusetts General Hospital, discusses fluorescence-guided glioma surgery, recently approved by the FDA.
-
Partnering to Treat Acoustic Neuroma
Massachusetts General Hospital, in partnership with Mass Eye and Ear, has created multidisciplinary relationships between surgeons, radiation oncologists, neuro-oncologists, audiologists and rehabilitation specialists for the treatment of patients with acoustic neuromas.
-
Gene Fusions Detected in Plasma of Glioblastoma Patients, Suggesting New Approach to Liquid Biopsy
A liquid biopsy based on RNA sequencing was feasible for profiling transcriptome-level gene fusions in extracellular vesicles derived from the plasma of patients with glioblastoma.
-
Patient-derived Dopamine Neurons Show Promise in Parkinson's Treatment
Massachusetts General Hospital and McClean Hospital researchers take significant steps towards proving the safety and efficacy of dopaminergic neuron implantation to treat Parkinson's disease.
-
Collaboration in Developing New Cell Therapy
In this video, Bob S. Carter, MD, PhD, Kwang-Soo Kim, PhD, Todd M. Herrington, MD, PhD, and Jeffrey S. Schweitzer, MD, PhD, discuss their cross-disciplinary and multi-institutional collaboration to develop this new therapy.
-
First-In-Human Therapy with Stem Cell–derived Dopaminergic Progenitor Cells for Parkinson's Disease
Mass General researchers report substantial clinical improvement in a patient with Parkinson's disease after they implanted midbrain dopaminergic progenitor cells that they differentiated in vitro from autologous induced pluripotent stem cells.
-
Liquid Biopsy Using Fluorescent Extracellular Vesicles Shows Promise for Diagnosis of Glioma
For patients suspected of having malignant glioma, detecting and analyzing fluorescent extracellular vesicles after administering 5-aminolevulinic acid oral solution may allow minimally invasive diagnosis.
-
Endonasal Surgery Using High-Speed Drill Puts Health Care Team at Risk of COVID-19
High-speed drilling appears to be the single greatest risk factor for potentially infectious aerosolization of new coronavirus during endonasal surgery, even when activated for only several seconds.
-
Multimodal Approach to Unruptured Cerebral Arteriovenous Malformations Tops ARUBA Outcomes
Tertiary referral centers such as Massachusetts General Hospital, which have thorough expertise in microsurgery, embolization and radiosurgery, may achieve better outcomes for patients with unruptured cerebral arteriovenous malformations than those reported in the ARUBA trial.
-
Novel Implantation Technique May Enhance Outcomes of Intracerebral Cell Therapy
Intracerebral "columnar injection" of stem cells, in which the track created by the surgical cannula is the site of cell deposition, may lead to more efficient cell transplantation and better functional outcomes in Parkinson's disease.
-
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
-
Third-Generation CAR T-cell Therapy for Glioblastoma Is Effective in Animal Model
A new chimeric antigen receptor T-cell strategy for glioblastoma, developed at Massachusetts General Hospital and proven effective in mice, relies on co-culturing the T cells with artificial antigen-presenting cells that express co-stimulatory molecules, to boost T-cell activation and persistence.
-
New Research and Treatment Options for IDH1 Mutant Tumors
In this video, Bob Carter, MD, PhD, describes the work of Daniel Cahill, MD, PhD, who is leading research on IDH1 mutant brain tumors.
-
The Mass General Neurosurgery Mission
Researchers from the Department of Neurosurgery at Massachusetts General Hospital discuss their collaborative work in clinical and translational research.
-
Treating Brain Tumors with Car T-Cells
In this video, Bob Carter, MD, PhD, chief of Neurosurgery Service, discusses an active research program at Massachusetts General Hospital that's involved in developing Car T-cell therapy for brain tumors.
-
Advances in Treatments for Movement Disorders
Two Mass General neurosurgeons give prominent examples of the hospital’s expertise in functional neurosurgery.
-
Specialization Improves Neurosurgery Outcomes Regardless of Case Volume
In breast cancer, vascular and cardiothoracic surgery, patient outcomes are better for subspecialists than for general surgeons. Mass General researchers investigated whether specialization in spinal or cranial surgery is associated with improved patient outcomes.
-
Establishing Reconstructive Neurosurgery as a Subspecialty
Despite the establishment of eight neurosurgical subspecialties, there’s a hole in patient care: restoration of function after the acute stage of paralysis or paresis. Bob S. Carter, MD, PhD, chief of Neurosurgery at Mass General, and colleagues present the rationale for an additional subspecialty.
-
How Liquid Biopsy Could Improve Brain Tumor Treatment and Diagnoses
Mass General doctors are developing a liquid biopsy for brain tumors to reduce the need for invasive tissue biopsies.
-
Bob Carter, MD, PhD Reflects on His First Year as Chief of Neurosurgery
As he reflects on the first year in his new position, Dr. Bob Carter discusses what made him come back to Mass General, recent research projects he's worked on and more.
Biography
Bob S. Carter, MD., PhD. is the Chair of the Department of Neurosurgery at Mass General and Visiting Professor at Harvard Medical School. One of the nation’s leading clinical neurosurgeons, Dr. Carter co-leads Mass General’s brain tumor program, which brings together over 100 faculty and staff focused on brain tumor clinical care, research and education.
As a prolific researcher, Dr. Carter's scientific work has included the development of the first reported EGFRvIII directed CAR T-cell therapy, and the first characterizations of exosomes in glioblastoma. He is a principal investigator participating in the NIH-funded Extracellular RNA Communication Consortium. Dr. Carter leads a team of clinician scientists who have developed the role of “big data” in characterizing outcomes in oncologic and vascular neurosurgery.
Dr. Carter is extensively published, and he lectures internationally on neurosurgery topics. He is an editorial board member for the Journal of Neurosurgery and editorial advisory board member for Neurosurgery.
Prior to joining Mass General, Dr. Carter served as Professor and Chair of Neurosurgery at the UC San Diego School of Medicine.
Consistently elected to America's Top Doctors®, Dr. Carter is a fellow of the American Association of Neurological Surgeons and a member of numerous medical organizations, including the Congress of Neurological Surgeons and the American Academy of Neurological Surgery. He serves on the program committee for the American Stroke Association’s International Stroke Conference and has served on the executive boards of the Joint Cerebrovascular Section and the New England Neurosurgical Society.
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.